Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Comment by CleverInvestor2on Apr 14, 2020 10:27am
129 Views
Post# 30907107

RE:RE:RE:RE:RE:RE:RE:Been holding up well

RE:RE:RE:RE:RE:RE:RE:Been holding up well
It looks like we're going to be making another run up like earlier this year. The momentum is back and investors like good buisness plans and strong healthy financial sheets. Trillium has enough money to last them until 2022. By then we should have a clear picture if trillium is a winner or not. If it's a winner, we can get another PP at much higher values to keep us afloat or.... Possible buyout.
<< Previous
Bullboard Posts
Next >>